Skip to content
Screener

Arcus Biosciences RCUS Restricted Cash

Restricted Cash at other companies

Merck & Co. logo
Merck & Co.MRK
$42M-36.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.2M-48.5%
Immunome logo
ImmunomeIMNM
$210K0.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.28M+164%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$316K-0.6%
Incyte logo
IncyteINCY
$1.82M-1.5%

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M—
EPS (diluted)-$0.72—

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-—
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.64B+275%
Enterprise value$3.61B+333%
P/S31.2×+27.4×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%—

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044

FAQ

What is Arcus Biosciences's restricted cash?
Arcus Biosciences (RCUS) reported restricted cash of $3M in Q2 2026.
How has Arcus Biosciences's restricted cash changed year-over-year?
Arcus Biosciences's restricted cash decreased by 0.0% year-over-year, from $3M to $3M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Arcus Biosciences's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude